• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Bristol-Myers Squibb - Articles and news items

needle-injection

FDA approves Bristol-Myers Squibb’s Opdivo as first Immuno-Oncology treatment

Industry news / 17 November 2016 / Niamh Louise Marriott, Digital Content Producer

Opdivo is the first and only Immuno-Oncology treatment proven in a Phase 3 trial to significantly extend overall survival for these patients…

cdf-all-approved

NICE approves three quarters of CDF drugs for routine NHS use

Industry news / 17 November 2016 / Niamh Louise Marriott, Digital Content Producer

More than 75% of treatments in the Cancer Drugs Fund (CDF) which have been reappraised by the National Institute for Health and Care Excellence (NICE) have received positive recommendations for routine use in the NHS. NICE has been reappraising cancer drugs which had not been recommended in previous NICE guidance (11 drug indications in total), […]

solid-tumours

Bristol-Myers Squibb and Infinity to collaborate on Opdivo (nivolumab) plus IPI-549 solid tumours study

Industry news / 11 November 2016 / Niamh Louise Marriott, Digital Content Producer

Bristol-Myers Squibb and Infinity will collaborate on a solid tumours trial to evaluate Bristol-Myers Squibb’s Opdivo in combination with Infinity’s…

 

Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +